$599
LEADER Adcom Vote (17-2) in Favor of CV Indication
The FDA advisory committee voted overwhelmingly in favor that Novo’s Victoza CVOT, LEADER, demonstrates liraglutide 1.8mg does not have excess CV risk (19-0) and provides substantial evidence that it reduces CV risk in patients with T2DM (17-2).